Activity of phenothiazines against medically important yeasts
- 1 May 1987
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 31 (5) , 834-836
- https://doi.org/10.1128/aac.31.5.834
Abstract
Two phenothiazine compounds, trifluoperazine and chlorpromazine, inhibited growth in vitro of the five most common pathogenic yeasts, with MICs ranging from 10 to 40 micrograms/ml. Daily intraperitoneal injections of trifluoperazine (4 to 7 mg/kg of body weight) increased the survival of mice experimentally infected with Candida albicans or Cryptococcus neoformans. The potential use of these drugs against fungal meningitis is discussed.This publication has 11 references indexed in Scilit:
- Activity of compound G2 isolated from alfalfa roots against medically important yeastsAntimicrobial Agents and Chemotherapy, 1986
- Active Extrusion of Potassium in the Yeast Saccharomyces cerevisiae Induced by Low Concentrations of TrifluoperazineMicrobiology, 1985
- Effects of phenothiazines on inhibition of plasma membrane ATPase and hyperpolarization of cell membranes in the yeast Saccharomyces cerevisiaeBiochimica et Biophysica Acta (BBA) - Biomembranes, 1984
- Medical mycology in crisis.1983
- Membrane effects of phenothiazines in yeasts. I. Stimulation of calcium and potassium fluxesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1983
- Antifungal Agents Used in Systemic Mycoses Activity and Therapeutic UseDrugs, 1983
- The Pharmacology and Clinical Effectiveness of Phenothiazines and Related Drugs for Managing Chemotherapy-induced EmesisDrugs, 1983
- Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United StatesAntimicrobial Agents and Chemotherapy, 1982
- Aspergillosis and other systemic mycoses. The growing problemJAMA, 1979
- Infections in cancer patientsCancer Treatment Reviews, 1975